Loading...
Amplia Therapeutics Limited
ATX.AX•ASX
Healthcare
Biotechnology
A$0.23
A$-0.01(-4.17%)
Amplia Therapeutics Limited (ATX.AX) Financial Performance & Income Statement Overview
Review Amplia Therapeutics Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
274.34%
↑ 274.34%
Operating Income Growth
40.81%
↑ 40.81%
Net Income Growth
27.86%
↑ 27.86%
Operating Cash Flow Growth
3.07%
↑ 3.07%
Operating Margin
-178.86%
↓ 178.86%
Gross Margin
88.23%
↑ 88.23%
Net Profit Margin
-181.41%
↓ 181.41%
ROE
-51.16%
↓ 51.16%
ROIC
-47.71%
↓ 47.71%
Amplia Therapeutics Limited (ATX.AX) Income Statement & Financial Overview
Review Amplia Therapeutics Limited's (ATX.AX) income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $1.41M | $2.004M | $2.45M | -$579895.00 |
| Cost of Revenue | $71023.00 | $330574.00 | $42949.00 | $44376.00 |
| Gross Profit | $1.34M | $1.67M | $2.41M | -$624271.00 |
| Gross Profit Ratio | $0.95 | $0.84 | $0.98 | $1.08 |
| R&D Expenses | $2.80M | $3.61M | $2.19M | $1.16M |
| SG&A Expenses | $1.34M | $1.43M | $1.37M | $1.59M |
| Operating Expenses | $4.09M | $5.02M | $3.57M | $2.75M |
| Total Costs & Expenses | $4.17M | $5.35M | $3.61M | $2.80M |
| Interest Income | $0.00 | $66550.00 | $78551.00 | $83491.00 |
| Interest Expense | $0.00 | $31849.00 | $46632.00 | $37705.00 |
| Depreciation & Amortization | $43361.00 | $43200.00 | $42949.00 | $44376.00 |
| EBITDA | -$2.80M | -$3.44M | -$1.12M | -$2.67M |
| EBITDA Ratio | -$1.99 | -$1.72 | -$0.46 | $4.75 |
| Operating Income | -$2.76M | -$3.34M | -$3.61M | -$2.80M |
| Operating Income Ratio | -$1.96 | -$1.67 | -$1.47 | $4.82 |
| Other Income/Expenses (Net) | -$55226.00 | -$2.02M | $31919.00 | $45786.00 |
| Income Before Tax | -$2.81M | -$5.36M | -$3.58M | -$2.75M |
| Income Before Tax Ratio | -$2.000 | -$2.68 | -$1.46 | $4.74 |
| Income Tax Expense | $0.00 | -$1.99M | -$2.45M | $579895.00 |
| Net Income | -$2.81M | -$3.37M | -$1.13M | -$3.33M |
| Net Income Ratio | -$2.000 | -$1.68 | -$0.46 | $5.74 |
| EPS | -$0.01 | -$0.02 | -$0.006 | -$0.02 |
| Diluted EPS | -$0.01 | -$0.02 | -$0.006 | -$0.02 |
| Weighted Avg Shares Outstanding | $253.55M | $193.79M | $199.62M | $199.62M |
| Weighted Avg Shares Outstanding (Diluted) | $253.70M | $194.006M | $199.62M | $199.62M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan